“I have had numerous interactions with the Bourne Partners M&A advisory team over the years. Their straightforward advice and thorough knowledge of the pharma / pharma services sector led us to two successful transactions. I would recommend them as a lead advisor to anyone seeking a specialist in the industry.”
- Paul Campanelli
Chief Executive Officer, Endo International plc
“The Bourne team worked diligently and added value in the evaluation and negotiation phases of the AMRI transaction. Their insight, experience and understanding of the CDMO and pharma sectors proved extremely useful and insightful. We also look forward to their investment and involvement alongside Carlyle in AMRI’s future growth strategy.”
- Stephen Wise
Managing Director & Global Head of Healthcare, The Carlyle Group
“Bourne Partners’ experienced execution team, deep domain knowledge and extensive strategic and PE relationships were critical in maximizing the value of the sale of Accelovance and Optimal Research. I highly recommend them as a sell-side advisor in the Clinical CRO and Sites Network space.”
- Stephen Trevisan
President & Chief Executive Officer, Accelovance, Inc
“I highly recommend Bourne Partners as a sell-side advisor in the consumer health space. Their deep industry knowledge and extensive relationships were critical in maximizing the value of the sale of our flagship brand, Cold-EEZE Cold Remedy.”
- Ted Karkus
Chief Executive Officer, Prophase Labs, Inc.
“I would highly recommend Bourne Partners as a financial advisor to anyone in the healthcare industry. Unlike other advisory firms, they have actually invested in and operated other pharmaceutical companies, so they bring a unique perspective to the table. Their experience and industry insight were invaluable in bringing our transaction to fruition.”
- Jack Davis
CEO, Covis Pharma Holdings Sarl
The above testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success.